PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer – topic of research paper in Clinical medicine. Download
Bureau et comité d'administration | FMC-HGE
Pharmacogenomics & Therapeutic optimization
More efficient and inclusive time-to-event trials with covariate adjustment: a simulation study